1
|
Weston DJ, Thomas S, Boyle GW, Pieren M. Alpibectir: Early Qualitative and Quantitative Metabolic Profiling from a First-Time-in-Human Study by Combining 19F-NMR (Nuclear Magnetic Resonance), 1H-NMR, and High-Resolution Mass Spectrometric Analyses. Drug Metab Dispos 2024; 52:858-874. [PMID: 38769017 DOI: 10.1124/dmd.124.001562] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2024] [Revised: 05/10/2024] [Accepted: 05/13/2024] [Indexed: 05/22/2024] Open
Abstract
Alpibectir (also known as BVL-GSK098 and GSK3729098) is a new chemical entity (NCE) with a novel mechanism for the treatment of tuberculosis. The disposition of alpibectir was determined in subjects from a first-time-in-human trial after a single oral dose of 40 mg and after 7 days repeat dosing at 30 mg. Here we present a combined approach of 19F-NMR (nuclear magnetic resonance), 1H-NMR, and high-resolution mass spectrometry (HRMS) to confidently determine the human metabolic fate of alpibectir. Utilizing multiple sites of fluorination in the molecule, it was possible to fractionate human urine and plasma to confidently detect and quantify the metabolite responses using 19F-NMR. Qualitative detection and structural characterization of F-containing NMR fractions were performed using complementary high-resolution ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) analyses to further add confidence to the metabolite responses in these fractions. Subsequent 1H-NMR then provided unequivocal standard-free structural confirmation for key metabolites, which would not be possible with conventional radioactivity detection and LC-MS/MS techniques. Alpibectir was shown to undergo extensive hydrolysis of the central amide moiety, where the resultant N-dealkylated amine and trifluorobutyric acid products were detected initially by unbiased 19F-NMR detection along with major downstream biotransformations to form a carbamoyl glucuronide conjugate and trifluoroacetic acid, respectively. Parallel UHPLC-MS/MS analyses provided confirmatory or additional structural characterization only where relevant. These concerted data allowed for the qualitative metabolic profile and quantitative determination of drug-related material (DRM) in urine and plasma, along with the percentage of dose excreted in urine, to be reported in a comprehensive, efficient, and data-led manner. SIGNIFICANCE STATEMENT: Combining the selectivity of 19F-NMR (nuclear magnetic resonance) for unfractionated samples as first-intent, data-led sample fractionation prior to 19F-NMR and structure-rich 1H-NMR detection, along with the sensitivity of high-resolution ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), a novel alternative for time-efficient detection and quantification of drug-related material (DRM) in human without use of radiolabeled drug is reported. This allowed more complete data rationalization of human metabolism, permitting early risk assessment and progression of the development of antitubercular agent, alpibectir.
Collapse
Affiliation(s)
- Daniel J Weston
- Disposition and Biotransformation (D.J.W., S.T.) and DMPK Projects Group (G.W.B.), GSK, Stevenage, United Kingdom; and BioVersys AG, Basel, Switzerland (M.P.)
| | - Steve Thomas
- Disposition and Biotransformation (D.J.W., S.T.) and DMPK Projects Group (G.W.B.), GSK, Stevenage, United Kingdom; and BioVersys AG, Basel, Switzerland (M.P.)
| | - Gary W Boyle
- Disposition and Biotransformation (D.J.W., S.T.) and DMPK Projects Group (G.W.B.), GSK, Stevenage, United Kingdom; and BioVersys AG, Basel, Switzerland (M.P.)
| | - Michel Pieren
- Disposition and Biotransformation (D.J.W., S.T.) and DMPK Projects Group (G.W.B.), GSK, Stevenage, United Kingdom; and BioVersys AG, Basel, Switzerland (M.P.)
| |
Collapse
|
2
|
Li W, Vazvaei-Smith F, Dear G, Boer J, Cuyckens F, Fraier D, Liang Y, Lu D, Mangus H, Moliner P, Pedersen ML, Romeo AA, Spracklin DK, Wagner DS, Winter S, Xu XS. Metabolite Bioanalysis in Drug Development: Recommendations from the IQ Consortium Metabolite Bioanalysis Working Group. Clin Pharmacol Ther 2024; 115:939-953. [PMID: 38073140 DOI: 10.1002/cpt.3144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Accepted: 12/05/2023] [Indexed: 03/13/2024]
Abstract
The intent of this perspective is to share the recommendations of the International Consortium for Innovation and Quality in Pharmaceutical Development Metabolite Bioanalysis Working Group on the fit-for-purpose metabolite bioanalysis in support of drug development and registration. This report summarizes the considerations for the trigger, timing, and rigor of bioanalysis in the various assessments to address unique challenges due to metabolites, with respect to efficacy and safety, which may arise during drug development from investigational new drug (IND) enabling studies, and phase I, phase II, and phase III clinical trials to regulatory submission. The recommended approaches ensure that important drug metabolites are identified in a timely manner and properly characterized for efficient drug development.
Collapse
Affiliation(s)
- Wenkui Li
- Pharmacokinetic Sciences, Novartis Biomedical Research, East Hanover, New Jersey, USA
| | - Faye Vazvaei-Smith
- Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc., West Point, Pennsylvania, USA
| | - Gordon Dear
- Drug Metabolism and Pharmacokinetics, GSK, Ware, UK
| | - Jason Boer
- Drug Metabolism and Pharmacokinetics, Incyte Corporation, Wilmington, Delaware, USA
| | - Filip Cuyckens
- Drug Metabolism and Pharmacokinetics, Janssen R & D, Beerse, Belgium
| | - Daniela Fraier
- Pharmaceutical Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Yuexia Liang
- Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc., West Point, Pennsylvania, USA
| | - Ding Lu
- Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals Inc., Boston, Massachusetts, USA
| | - Heidi Mangus
- Drug Metabolism and Pharmacokinetics, Agios Pharmaceuticals Inc., Cambridge, Massachusetts, USA
| | - Patricia Moliner
- Enzymology and Metabolism, Department of Translational Medicine and Early Development, Sanofi, Montpellier, Occitanie, France
| | - Mette Lund Pedersen
- DMPK, Research and Early Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
| | - Andrea A Romeo
- Pharmaceutical Sciences, F. Hoffmann-La Roche Ltd, Basel, Switzerland
| | - Douglas K Spracklin
- Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Groton, Connecticut, USA
| | - David S Wagner
- Drug Metabolism and Disposition, AbbVie, North Chicago, Illinois, USA
| | - Serge Winter
- Pharmacokinetic Sciences, Novartis Biomedical Research, Basel, Switzerland
| | - Xiaohui Sophia Xu
- Clinical Bioanalysis, Translation Medicine, Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA
| |
Collapse
|
3
|
Young GC, Spracklin DK, James AD, Hvenegaard MG, Scarfe G, Wagner DS, Georgi K, Schieferstein H, Bjornsdottir I, van Groen B, Romeo AA, Cassidy KC, Da-Violante G, Bister B, Blech S, Lyer R, Schulz SI, Cuyckens F, Moliner P. Considerations for Human ADME Strategy and Design Paradigm Shift(s) - An Industry White Paper. Clin Pharmacol Ther 2023; 113:775-781. [PMID: 35733280 DOI: 10.1002/cpt.2691] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Accepted: 06/15/2022] [Indexed: 11/10/2022]
Abstract
The human absorption, distribution, metabolism, and excretion (hADME) study is the cornerstone of the clinical pharmacology package for small molecule drugs, providing comprehensive information on the rates and routes of disposition and elimination of drug-related material in humans through the use of 14 C-labeled drug. Significant changes have already been made in the design of the hADME study for many companies, but opportunity exists to continue to re-think both the design and timing of the hADME study in light of the potential offered by newer technologies, that enable flexibility in particular to reducing the magnitude of the radioactive dose used. This paper provides considerations on the variety of current strategies that exist across a number of pharmaceutical companies and on some of the ongoing debates around a potential move to the so called "human first/human only" approach, already adopted by at least one company. The paper also provides a framework for continuing the discussion in the application of further shifts in the paradigm.
Collapse
Affiliation(s)
- Graeme C Young
- GlaxoSmithKline Research & Development Ltd., David Jack Centre, Ware, UK
| | | | | | | | - Graeme Scarfe
- AstraZeneca, Cambridge Biomedical Campus, Cambridge, UK
| | | | - Katrin Georgi
- The Healthcare Business of Merck KGaA, Darmstadt, Germany
| | | | | | | | - Andrea A Romeo
- Roche Pharma Research and Early Development, Basel, Switzerland
| | | | | | - Bojan Bister
- Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
| | - Stefan Blech
- Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach, Germany
| | | | | | | | | |
Collapse
|
4
|
Weston DJ, Dave M, Colizza K, Thomas S, Tomlinson L, Gregory R, Beaumont C, Pirhalla J, Dear GJ. A Discovery Biotransformation Strategy: Combining In Silico Tools with High-Resolution Mass Spectrometry and Software-Assisted Data Analysis for High-Throughput Metabolism. Xenobiotica 2022; 52:928-942. [PMID: 36227740 DOI: 10.1080/00498254.2022.2136042] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Understanding compound metabolism in early drug discovery aids medicinal chemistry in designing molecules with improved safety and ADME properties. While advancements in metabolite prediction brings increasedconfidence, structural decisions require experimental data. In vitro metabolism studies using liquid chromatography and high-resolution mass spectrometry (LC-MS) are generally resource intensive and performed on very few compounds, limiting the chemical space that can be examined.Here, we describe a novel metabolism strategy increasing compound throughput using residual in vitro clearance samples conducted at drug concentrations of 0.5 µM. Analysis by robust UHPLC separation and accurate-mass MS detection ensures major metabolites are identified from a single injection. In silico prediction (parent cLogD) tailors chromatographic conditions, with data-dependent MS/MS targeting predicted metabolites. Software-assisted data mining, structure elucidation and automatic reporting are used.Confidence in the globally-aligned workflow is demonstrated with sixteen marketed drugs. The approach is now implemented routinely across our laboratories. To date, the success rate for identification of at least one major metabolite is 85%. The utility of these data has been demonstrated across multiple projects, allowing earlier medicinal chemistry decisions to increase efficiency and impact of the design-make-test cycle; thus improving the translatability of early in vitro metabolism data.
Collapse
Affiliation(s)
- Daniel J Weston
- GSK, DMPK, Disposition and Biotransformation, Gunnels Wood Road, Stevenage, SG1 2NY, UK
| | - Mehul Dave
- GSK, DMPK, Disposition and Biotransformation, Gunnels Wood Road, Stevenage, SG1 2NY, UK
| | - Kevin Colizza
- GSK, DMPK, Disposition and Biotransformation, 1250 S. Collegeville Road., Collegeville, PA 19426, USA
| | - Steve Thomas
- GSK, DMPK, Disposition and Biotransformation, Gunnels Wood Road, Stevenage, SG1 2NY, UK
| | - Laura Tomlinson
- GSK, DMPK, Discovery DMPK, Gunnels Wood Road, Stevenage, SG1 2NY, UK
| | - Richard Gregory
- GSK, DMPK, Discovery DMPK, Gunnels Wood Road, Stevenage, SG1 2NY, UK
| | - Claire Beaumont
- GSK, DMPK, Disposition and Biotransformation, Gunnels Wood Road, Stevenage, SG1 2NY, UK
| | - Jill Pirhalla
- GSK, DMPK, Disposition and Biotransformation, 1250 S. Collegeville Road., Collegeville, PA 19426, USA
| | - Gordon J Dear
- GSK, DMPK, Disposition and Biotransformation, Gunnels Wood Road, Stevenage, SG1 2NY, UK
| |
Collapse
|
5
|
Ivashchenko DA, Cerqueira NM, Magalhães AL. Improving computational modeling coupled with ion mobility-mass spectrometry data for efficient drug metabolite structural determination. Struct Chem 2021. [DOI: 10.1007/s11224-021-01726-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Montes-Grajales D, Esturau-Escofet N, Esquivel B, Martinez-Romero E. Exo-Metabolites of Phaseolus vulgaris-Nodulating Rhizobial Strains. Metabolites 2019; 9:E105. [PMID: 31151153 PMCID: PMC6630823 DOI: 10.3390/metabo9060105] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2019] [Revised: 03/15/2019] [Accepted: 03/18/2019] [Indexed: 01/01/2023] Open
Abstract
Rhizobia are able to convert dinitrogen into biologically available forms of nitrogen through their symbiotic association with leguminous plants. This results in plant growth promotion, and also in conferring host resistance to different types of stress. These bacteria can interact with other organisms and survive in a wide range of environments, such as soil, rhizosphere, and inside roots. As most of these processes are molecularly mediated, the aim of this research was to identify and quantify the exo-metabolites produced by Rhizobium etli CFN42, Rhizobium leucaenae CFN299, Rhizobium tropici CIAT899, Rhizobium phaseoli Ch24-10, and Sinorhizobium americanum CFNEI156, by nuclear magnetic resonance (NMR). Bacteria were grown in free-living cultures using minimal medium containing sucrose and glutamate. Interestingly, we found that even when these bacteria belong to the same family (Rhizobiaceae) and all form nitrogen-fixing nodules on Phaseolus vulgaris roots, they exhibited different patterns and concentrations of chemical species produced by them.
Collapse
Affiliation(s)
- Diana Montes-Grajales
- Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México, Cuernavaca 62210, Mexico.
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
- Environmental and Computational Chemistry Group, University of Cartagena, Cartagena 130015, Colombia.
| | - Nuria Esturau-Escofet
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
| | - Baldomero Esquivel
- Instituto de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
| | | |
Collapse
|
7
|
Schadt S, Bister B, Chowdhury SK, Funk C, Hop CECA, Humphreys WG, Igarashi F, James AD, Kagan M, Khojasteh SC, Nedderman ANR, Prakash C, Runge F, Scheible H, Spracklin DK, Swart P, Tse S, Yuan J, Obach RS. A Decade in the MIST: Learnings from Investigations of Drug Metabolites in Drug Development under the “Metabolites in Safety Testing” Regulatory Guidance. Drug Metab Dispos 2018; 46:865-878. [DOI: 10.1124/dmd.117.079848] [Citation(s) in RCA: 53] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2017] [Accepted: 02/21/2018] [Indexed: 11/22/2022] Open
|
8
|
Gong Y, Chen J, Shi Y, Lim HK, Weng N, Salter R. Standard-Free Bioanalytical Approach for Absolute Quantitation of Drug Metabolites Utilizing Biosynthesis of Reciprocal Radio and Stable Isotopologues and Its Application. Anal Chem 2017; 89:8399-8404. [DOI: 10.1021/acs.analchem.7b01830] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Yong Gong
- Department of Pharmacokinetics Dynamics & Metabolism, Janssen Research & Development, Johnson & Johnson, Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Jie Chen
- Department of Pharmacokinetics Dynamics & Metabolism, Janssen Research & Development, Johnson & Johnson, Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Yifan Shi
- Department of Pharmacokinetics Dynamics & Metabolism, Janssen Research & Development, Johnson & Johnson, Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Heng-Keang Lim
- Department of Pharmacokinetics Dynamics & Metabolism, Janssen Research & Development, Johnson & Johnson, Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Naidong Weng
- Department of Pharmacokinetics Dynamics & Metabolism, Janssen Research & Development, Johnson & Johnson, Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| | - Rhys Salter
- Department of Pharmacokinetics Dynamics & Metabolism, Janssen Research & Development, Johnson & Johnson, Welsh & McKean Roads, Spring House, Pennsylvania 19477, United States
| |
Collapse
|
9
|
James AD, Marvalin C, Luneau A, Meissner A, Camenisch G. Comparison of 19F NMR and 14C Measurements for the Assessment of ADME of BYL719 (Alpelisib) in Humans. Drug Metab Dispos 2017; 45:900-907. [DOI: 10.1124/dmd.117.075424] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Accepted: 05/22/2017] [Indexed: 01/15/2023] Open
|
10
|
Reading E, Munoz-Muriedas J, Roberts AD, Dear GJ, Robinson CV, Beaumont C. Elucidation of Drug Metabolite Structural Isomers Using Molecular Modeling Coupled with Ion Mobility Mass Spectrometry. Anal Chem 2016; 88:2273-80. [DOI: 10.1021/acs.analchem.5b04068] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Affiliation(s)
- Eamonn Reading
- Department
of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford OX1 3QZ, U.K
| | - Jordi Munoz-Muriedas
- Chemical
Sciences, Computational Chemistry, GlaxoSmithKline, Stevenage, Hertfordshire SG1 2NY, U.K
| | - Andrew D. Roberts
- Drug
Metabolism and Pharmacokinetics, GlaxoSmithKline, Ware, Hertfordshire SG12 0DP, U.K
| | - Gordon J. Dear
- Drug
Metabolism and Pharmacokinetics, GlaxoSmithKline, Ware, Hertfordshire SG12 0DP, U.K
| | - Carol V. Robinson
- Department
of Chemistry, Physical and Theoretical Chemistry Laboratory, University of Oxford, Oxford OX1 3QZ, U.K
| | - Claire Beaumont
- Drug
Metabolism and Pharmacokinetics, GlaxoSmithKline, Ware, Hertfordshire SG12 0DP, U.K
| |
Collapse
|
11
|
Beaumont C, Young GC, Cavalier T, Young MA. Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches. Br J Clin Pharmacol 2015; 78:1185-200. [PMID: 25041729 DOI: 10.1111/bcp.12468] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2014] [Accepted: 07/07/2014] [Indexed: 01/19/2023] Open
Abstract
Human radiolabel studies are traditionally conducted to provide a definitive understanding of the human absorption, distribution, metabolism and excretion (ADME) properties of a drug. However, advances in technology over the past decade have allowed alternative methods to be employed to obtain both clinical ADME and pharmacokinetic (PK) information. These include microdose and microtracer approaches using accelerator mass spectrometry, and the identification and quantification of metabolites in samples from classical human PK studies using technologies suitable for non-radiolabelled drug molecules, namely liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy. These recently developed approaches are described here together with relevant examples primarily from experiences gained in support of drug development projects at GlaxoSmithKline. The advantages of these study designs together with their limitations are described. We also discuss special considerations which should be made for a successful outcome to these new approaches and also to the more traditional human radiolabel study in order to maximize knowledge around the human ADME properties of drug molecules.
Collapse
Affiliation(s)
- Claire Beaumont
- Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Park Road, Ware, Hertfordshire, SG12 0DP, UK
| | | | | | | |
Collapse
|
12
|
Analytical challenges for conducting rapid metabolism characterization for QIVIVE. Toxicology 2015; 332:20-9. [DOI: 10.1016/j.tox.2013.08.010] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2012] [Revised: 08/05/2013] [Accepted: 08/13/2013] [Indexed: 12/22/2022]
|
13
|
Pellegatti M. The debate on animal ADME studies in drug development: an update. Expert Opin Drug Metab Toxicol 2014; 10:1615-20. [PMID: 25373428 DOI: 10.1517/17425255.2015.979152] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
The preparation and release of the International Conference on Harmonisation guideline on safety evaluation of human metabolites and the technical progresses in bioanalysis have triggered an intense debate on the value of absorption, distribution, metabolism and excretion radiolabelled studies in animals. Some authors have radically challenged the traditional approach whereas others, while accepting the need of significant changes, argue that these studies remain an irreplaceable component of the preclinical registration dossier. This paper reviews some of the representative positions and describes the potential evolution.
Collapse
|
14
|
Hoffmann E, Wald J, Lavu S, Roberts J, Beaumont C, Haddad J, Elliott P, Westphal C, Jacobson E. Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man. Br J Clin Pharmacol 2013; 75:186-96. [PMID: 22616762 DOI: 10.1111/j.1365-2125.2012.04340.x] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2012] [Accepted: 05/12/2012] [Indexed: 12/15/2022] Open
Abstract
AIM SRT2104 is a novel, first-in-class, highly selective small molecule activator of the NAD + dependent deacetylase SIRT1. SRT2104 was dosed to healthy male and female volunteers in a series of phase 1 clinical studies that were designed to elucidate tolerability and pharmacokinetics associated with oral dosing to aid in dose selection for subsequent clinical trials. METHODS In the first-in-human study, there was both a single dose phase and 7 day repeat dose phase. Doses used ranged from 0.03 to 3.0 g. A radioactive microtracer study was subsequently conducted to determine systemic clearance, bioavailability and preliminary metabolism, and a crossover study was conducted to determine the effect of gender, formulation and feeding state on SRT2104 pharmacokinetics. RESULTS SRT2104 was well tolerated in all of these studies, with no serious adverse reactions observed. SRT2104 displayed a dose-dependent, but sub-proportional increase in exposure following single dose and repeated dose administration. Accumulation of three-fold or less occurs after 7 days of repeat dosing. The mean bioavailability was circa 14% and the mean clearance was circa 400 ml min(-1). Although there were no substantial effects on exposure resulting from gender or formulation differences, a notable food effect was observed, manifested as up to four-fold increase in exposure parameters. CONCLUSIONS In the absence of an optimized formulation of SRT2104, the food effect can be used to maximize exposure in future clinical studies. Combined with the good tolerability of all doses demonstrated in these studies, the favourable selectivity profile of SRT2104 allows for the use of this SIRT1 modulator for target validation in the clinic.
Collapse
|
15
|
Bloomer JC, Nash M, Webb A, Miller BE, Lazaar AL, Beaumont C, Guiney WJ. Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling. Br J Clin Pharmacol 2013; 75:488-96. [PMID: 22670830 DOI: 10.1111/j.1365-2125.2012.04352.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2011] [Accepted: 05/15/2012] [Indexed: 11/30/2022] Open
Abstract
AIM Characterization of the biliary disposition of GSK1325756, using a non-invasive bile sampling technique and spectrometric analyses, to inform the major routes of metabolic elimination and to enable an assessment of victim drug interaction risk. METHOD Sixteen healthy, elderly subjects underwent non-invasive bile capture using a peroral string device (Entero-Test(®)) prior to and following a single oral dose of GSK1325756 (100 mg). The device was swallowed by each subject and once the weighted string was judged to have reached the duodenum, gallbladder contraction was stimulated in order to release bile. The string was then retrieved via the mouth and bile samples were analyzed for drug-related material using spectrometric and spectroscopic techniques following solvent extraction. RESULTS Nuclear magnetic resonance spectroscopy (NMR) indicated that the O-glucuronide metabolite was the major metabolite of GSK1325756, representing approximately 80% of drug-related material in bile. As bile is the major clearance route for GSK1325756 (only 4% of the administered dose was excreted in human urine), this result indicates that uridine 5'-diphospho-glucuronosyltransferases (UGTs) are the major drug metabolizing enzymes responsible for drug clearance. The relatively minor contribution made by oxidative routes reduces the concern of CYP-mediated victim drug interactions. CONCLUSION The results from this study demonstrate the utility of deploying the Entero-Test® in early human studies to provide information on the biliary disposition of drugs and their metabolites. This technique can be readily applied in early clinical development studies to provide information on the risk of interactions for drugs that are metabolized and eliminated in bile.
Collapse
|
16
|
|
17
|
Luffer-Atlas D. The early estimation of circulating drug metabolites in humans. Expert Opin Drug Metab Toxicol 2012; 8:985-97. [PMID: 22681256 DOI: 10.1517/17425255.2012.693159] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
INTRODUCTION An evolution in bioanalytical methodologies to identify and quantify drug metabolites has led to a wealth of biotransformation information during preclinical and early clinical testing phases. However, this abundance of metabolism data has not clarified how to select the most important circulating human metabolites for safety assessment. Consequently, more stringent regulatory expectations for a comprehensive approach to human metabolism have led pharmaceutical sponsors to employ a variety of novel methods to estimate circulating drug metabolites in humans and animals. AREAS COVERED This review provides context for 'why' human circulating metabolites must be qualified for safety in animals. A detailed overview is also presented concerning 'where,' 'how' and 'when' to conduct these assessments during drug development. EXPERT OPINION A human metabolite qualification strategy is now a required element of the drug safety package submitted with a new drug application (NDA). The important question is whether or not this additional information, about metabolite safety, is making human drugs any safer. Currently, this is a debatable issue, especially because stand-alone metabolite testing is fraught with its own challenges. As drug development moves into the twenty-first century, there is a pressing need for more sophisticated methodologies to address human drug and metabolite safety.
Collapse
Affiliation(s)
- Debra Luffer-Atlas
- Department of Drug Disposition, Lilly Research Laboratories, Indianapolis, IN 46285, USA.
| |
Collapse
|
18
|
Mutlib A, Espina R, Atherton J, Wang J, Talaat R, Scatina J, Chandrasekaran A. Alternate strategies to obtain mass balance without the use of radiolabeled compounds: application of quantitative fluorine (19F) nuclear magnetic resonance (NMR) spectroscopy in metabolism studies. Chem Res Toxicol 2012; 25:572-83. [PMID: 22292524 DOI: 10.1021/tx2005629] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Nuclear magnetic resonance (NMR) spectroscopy is playing an increasingly important role in the quantitation of small and large molecules. Recently, we demonstrated that (1)H NMR could be used to quantitate drug metabolites isolated in submilligram quantities from biological sources. It was shown that these metabolites, once quantitated by NMR, were suitable to be used as reference standards in quantitative LC/MS-based assays, hence circumventing the need for radiolabeled material or synthetic standards to obtain plasma exposure estimates in humans and preclinical species. The quantitative capabilities of high-field NMR is further demonstrated in the current study by obtaining the mass balance of fluorinated compounds using (19)F-NMR. Two fluorinated compounds which were radio-labeled with carbon-14 on metabolically stable positions were dosed in rats and urine and feces collected. The mass balance of the compounds was obtained initially by counting the radioactivity present in each sample. Subsequently, the same sets of samples were analyzed by (19)F-NMR, and the concentrations determined by this method were compared with data obtained using radioactivity counting. It was shown that the two methods produced comparable values. To demonstrate the value of this analytical technique in drug discovery, a fluorinated compound was dosed intravenously in dogs and feces and urine collected. Initial profiling of samples showed that this compound was excreted mainly unchanged in feces, and hence, an estimate of mass balance was obtained using (19)F-NMR. The data obtained by this method was confirmed by additional quantitative studies using mass spectrometry. Hence cross-validations of the quantitative (19)F-NMR method by radioactivity counting and mass spectrometric analysis were demonstrated in this study. A strategy outlining the use of fluorinated compounds in conjunction with (19)F-NMR to understand their routes of excretion or mass balance in animals is proposed. These studies demonstrate that quantitative (19)F-NMR could be used as an alternate technique to obtain an estimate of the mass balance of fluorinated compounds, especially in early drug development where attrition of the compounds is high, and cost savings could be realized through the use of such a technique rather than employing radioactive compounds. The potential application of qNMR in conducting early human ADME studies with fluorinated compounds is also discussed.
Collapse
Affiliation(s)
- Abdul Mutlib
- Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, 500 Arcola Road, Collegeville, Pennsylvania 19426, USA.
| | | | | | | | | | | | | |
Collapse
|
19
|
Pellegatti M. Preclinical in vivo ADME studies in drug development: a critical review. Expert Opin Drug Metab Toxicol 2012; 8:161-72. [PMID: 22248306 DOI: 10.1517/17425255.2012.652084] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
INTRODUCTION The last two decades have brought many fundamental changes to the drug development process. One such change is the importance of preclinical pharmacokinetics, which has become an essential part of early drug discovery. Furthermore, bioanalytical methods have become more sensitive and the identification and quantitation of metabolites can now be carried out on limited amount of biological material. There has also been a change in regulatory expectations, which are now particularly focused on the safety of human metabolites. AREAS COVERED The focus of this paper is on some 'traditional' in vivo ADME studies: excretion balance, metabolic profile and WBA in the toxicological species. These studies, performed with radiolabeled material, have a long history: and are a regular presence in submission dossiers. This paper reviews their value in the perspective of the contemporary drug development process. EXPERT OPINION These experiments may sometimes still be relevant to explain toxicological findings or for other special purposes but should not be considered required pieces of the registration dossiers. An appropriate investigation of samples coming from safety evaluation and human Phase I studies and the knowledge generated during the lead optimization phase provide, in most instances, all the DMPK information needed to take decisions in the drug development process.
Collapse
|
20
|
Guiney WJ, Beaumont C, Thomas SR, Robertson DC, McHugh SM, Koch A, Richards D. Use of Entero-Test, a simple approach for non-invasive clinical evaluation of the biliary disposition of drugs. Br J Clin Pharmacol 2011; 72:133-42. [PMID: 21366667 DOI: 10.1111/j.1365-2125.2011.03956.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
AIM To evaluate the non-invasive collection of bile from healthy human subjects for the qualitative characterization of the biliary disposition of a drug, using spectrometric techniques. METHODS Twenty subjects underwent non-invasive bile capture using a peroral string test (Entero-Test) device prior to and following a single oral dose of simvastatin (80 mg). The device, consisting of a weighted gelatin capsule containing a highly absorbent nylon string, was swallowed by each subject with the proximal end of the string taped to the face. Once the weighted string was judged to have reached the duodenum, gallbladder contraction was stimulated in order to release bile. The string was then retrieved via the mouth, and bile samples were analysed for drug-related material using spectrometric and spectroscopic techniques following solvent extraction. RESULTS Numerous metabolites of simvastatin were detected, and the major metabolites were consistent with those reported from studies where bile was collected using invasive techniques from patients dosed with [(14) C]-simvastatin. CONCLUSIONS The results from this study demonstrate the utility of deploying the Entero-Test in human studies to provide structural information on biliary metabolites. This can be readily applied in drug development studies, including those in the target patient population and may eliminate the need for more invasive sampling techniques.
Collapse
Affiliation(s)
- William J Guiney
- Toxicokinetics and Biotransformation, DMPK, Platform Technology and Science Department, GlaxoSmithKline, Park Road,Ware, Hertfordshire SG12 0DP, UK.
| | | | | | | | | | | | | |
Collapse
|
21
|
Obach RS, Nedderman AN, Smith DA. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica 2011; 42:46-56. [DOI: 10.3109/00498254.2011.621985] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
|
22
|
Accurate-mass instrumentation should not always be the first-and-only choice for MS in the drug metabolism environment. Bioanalysis 2011; 3:1795-8. [DOI: 10.4155/bio.11.169] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
|
23
|
Nedderman AN, Dear GJ, North S, Obach RS, Higton D. From definition to implementation: a cross-industry perspective of past, current and future MIST strategies. Xenobiotica 2011; 41:605-22. [DOI: 10.3109/00498254.2011.562330] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
|
24
|
NMR spectroscopy as a tool to close the gap on metabolite characterization under MIST. Bioanalysis 2011; 2:1263-76. [PMID: 21083239 DOI: 10.4155/bio.10.77] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
Withdrawals from the market due to unforeseen adverse events have triggered changes in the way therapeutics are discovered and developed. This has resulted in an emphasis on truly understanding the efficacy and toxicity profile of new chemical entities (NCE) and the contributions of their metabolites to on-target pharmacology and off-target receptor-mediated toxicology. Members of the pharmaceutical industry, scientific community and regulatory agencies have held dialogues with respect to metabolites in safety testing (MIST); and both the US FDA and International Conference on Harmonisation have issued guidances with respect to when and how to characterize metabolites for human safety testing. This review provides a brief overview of NMR spectroscopy as applied to the structure elucidation and quantification of drug metabolites within the drug discovery and development process. It covers advances in this technique, including cryogenic cooling of detection circuitry for enhanced sensitivity, hyphenated LC-NMR techniques, improved dynamic range through new solvent-suppression pulse sequences and quantitation. These applications add to the already diverse NMR toolkit and further anchor NMR as a technique that is directly applicable to meeting the requirements of MIST guidelines.
Collapse
|
25
|
Serres MD, Bowers G, Boyle G, Beaumont C, Castellino S, Sigafoos J, Dave M, Roberts A, Shah V, Olson K, Patel D, Wagner D, Yeager R, Serabjit-Singh C. Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 2011; 41:464-75. [DOI: 10.3109/00498254.2011.560295] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
26
|
Pellegatti M, Pagliarusco S. Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: a review. Expert Opin Drug Metab Toxicol 2011; 7:137-46. [DOI: 10.1517/17425255.2011.545053] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
27
|
Approaches for the rapid identification of drug metabolites in early clinical studies. Bioanalysis 2011; 3:197-213. [DOI: 10.4155/bio.10.186] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Understanding the metabolism of a novel drug candidate in drug discovery and drug development is as important today as it was 30 years ago. What has changed in this period is the technology available for proficient metabolite characterization from complex biological sources. High-efficiency chromatography, sensitive MS and information-rich NMR spectroscopy are approaches that are now commonplace in the modern laboratory. These advancements in analytical technology have led to unequivocal metabolite identification often being performed at the earliest opportunity, following the first dose to man. For this reason an alternative approach is to shift from predicting and extrapolating possible human metabolism from in silico and nonclinical sources, to actual characterization at steady state within early clinical trials. This review provides an overview of modern approaches for characterizing drug metabolites in these early clinical studies. Since much of this progress has come from technology development over the years, the review is concluded with a forward-looking perspective on how this progression may continue into the next decade.
Collapse
|
28
|
Walker GS, Ryder TF, Sharma R, Smith EB, Freund A. Validation of Isolated Metabolites from Drug Metabolism Studies as Analytical Standards by Quantitative NMR. Drug Metab Dispos 2010; 39:433-40. [DOI: 10.1124/dmd.110.036343] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
29
|
Dear GJ, Munoz-Muriedas J, Beaumont C, Roberts A, Kirk J, Williams JP, Campuzano I. Sites of metabolic substitution: investigating metabolite structures utilising ion mobility and molecular modelling. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2010; 24:3157-3162. [PMID: 20941763 DOI: 10.1002/rcm.4742] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Drug metabolism is an integral part of the drug development and drug discovery process. It is required to validate the toxicity of metabolites in support of safety testing and in particular provide information on the potential to form pharmacologically active or toxic metabolites. The current methodologies of choice for metabolite structural elucidation are liquid chromatography/tandem mass spectrometry (LC/MS/MS) and nuclear magnetic resonance (NMR) spectroscopy. There are, in certain cases, examples of metabolites whose sites of metabolism cannot be unequivocally identified by MS/MS alone. Utilising commercially available molecular dynamics packages and known quantum chemistry basis sets, an ensemble of lowest energy structures were generated for a group of aromatic hydroxylated metabolites of the model compound ondansetron. Theoretical collision cross-sections were calculated for each structure. Travelling-wave ion mobility (IMS) measurements were also performed on the compounds, thus enabling experimentally derived collision cross-sections to be calculated. A comparison of the theoretical and experimentally derived collision cross-sections were utilised for the accurate assignment of isomeric drug metabolites. The UPLC/IMS-MS method, described herein, demonstrates the ability to measure reproducibly by ion mobility, metabolite structural isomers, which differ in collision cross-section, both theoretical and experimentally derived, by less than 1 Å(2). This application has the potential to supplement and/or complement current methods of metabolite structural characterisation.
Collapse
Affiliation(s)
- Gordon J Dear
- PCD DMPK, GlaxoSmithKline, Ware, Hertfordshire SG12 0DP, UK
| | | | | | | | | | | | | |
Collapse
|
30
|
Mutlib A, Espina R, Vishwanathan K, Babalola K, Chen Z, Dehnhardt C, Venkatesan A, Mansour T, Chaudhary I, Talaat R, Scatina J. Application of Quantitative NMR in Pharmacological Evaluation of Biologically Generated Metabolites: Implications in Drug Discovery. Drug Metab Dispos 2010; 39:106-16. [DOI: 10.1124/dmd.110.032490] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
31
|
Looking back through the MIST: a perspective of evolving strategies and key focus areas for metabolite safety analysis. Bioanalysis 2010; 2:1235-48. [DOI: 10.4155/bio.10.71] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
The publication of the US FDA MIST guidance document in 2008 reignited the debate around the most appropriate strategies to underwrite metabolite safety for novel compounds. Whilst some organizations have suggested that the guidelines necessitate a paradigm shift to more thorough metabolite analysis during early development, an evaluation of historical practices shows that the principles of the guidelines have always largely underpinned metabolism studies within the pharmaceutical industry. Therefore, it is argued that existing practices, when coupled to appropriate emerging analytical tools and a case-by-case consideration of the relevance of the generated metabolism data in terms of structure, physicochemisty, abundance and activity, represent a fit-for-purpose approach to metabolite-safety assessments.
Collapse
|
32
|
Addressing metabolite safety during first-in-man studies using 14C-labeled drug and accelerator mass spectrometry. Bioanalysis 2010; 2:1315-24. [DOI: 10.4155/bio.10.87] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Active drug metabolites formed in humans but present in relatively low abundance in preclinical species can lead to unpredicted adverse effects during clinical use. The regulatory guidelines in recent years have therefore required that the metabolism of a drug be quantitatively compared between preclinical species and human at the earliest practicable stage of drug development. Amongst the variety of methods available, inclusion of low radioactive doses of 14C drug in first-in-man studies coupled to the sensitive analytical technology of accelerator MS (AMS) has found utility. Measurement of 14C by AMS allows for quantification of metabolites, even if their structures are unknown, and, when used in conjunction with LC–MS, can provide both quantitative and structural data. This review examines a typical approach to using AMS and associated analytical methods in addressing the regulatory guidelines and discusses a number of possible scenarios including the question of steady state.
Collapse
|
33
|
Guiney WJ, Beaumont C, Thomas SR. Use of the entero-test, a novel approach for the noninvasive capture of biliary metabolites in dogs. Drug Metab Dispos 2010; 38:851-6. [PMID: 20110404 DOI: 10.1124/dmd.109.031062] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Preclinical information on the biliary metabolites of a drug candidate is typically obtained through the collection of bile after surgical cannulation of the bile duct. In this study, we describe a novel approach using the Entero-Test, a simple device that facilitates the noninvasive sampling of duodenal bile. The Entero-Test was used to collect bile from six fasted dogs that had been dosed either orally with simvastatin (SV) or intravenously with simvastatin hydroxy acid (SVA), compounds that have been previously reported to undergo extensive metabolism and biliary secretion in the dog. The devices, consisting of a weighted gelatin capsule containing 90 cm of a highly absorbent nylon string, were swallowed by each dog with the proximal end of the string taped to the animal's face. Once the weighted string had reached the duodenum, gallbladder contraction was stimulated to release bile. Each bile-stained string was then retrieved via the mouth and, after solvent extraction, samples were analyzed for drug-related material by ultraperformance liquid chromatography-mass spectrometry and NMR spectroscopy. Numerous metabolites of SV and SVA were observed, and, in general, the major metabolites have been reported previously from studies with bile duct-cannulated animals dosed with [14C]SV or [14C]SVA. The results from this study demonstrate the utility of deploying the Entero-Test in absorption, distribution, metabolism, and elimination studies to provide information on the nature of biliary metabolites, which, on occasion, may be sufficient to negate the need for more invasive sampling techniques. The benefits and limitations of the technique are discussed.
Collapse
Affiliation(s)
- W J Guiney
- Toxicokinetics and Biotransformation, PCD DMPK Department, GlaxoSmithKline, Park Road, Ware, Hertfordshire SG120DP, UK.
| | | | | |
Collapse
|
34
|
Walker D, Brady J, Dalvie D, Davis J, Dowty M, Duncan JN, Nedderman A, Obach RS, Wright P. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem Res Toxicol 2010; 22:1653-62. [PMID: 19715349 DOI: 10.1021/tx900213j] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The subject of metabolites in safety testing has had much debate in the recent past and has shown itself to be a complex issue with no simple solutions to providing absolute assurance of drug safety. Much of the attention has focused on the ability to identify metabolites and then demonstrate that their risk has been adequately characterized, either through their exposure in toxicology species or, failing this, by direct safety testing. In this review, we summarize our forward operational strategy that combines the principles summarized in the FDA Guidance, together with discussions at scientific meetings and literature opinions. It is a balance between the primary goal of assuring patient safety with one of reasonable investment. A key principle in striking this balance is to build stepwise information on metabolites through the drug discovery and development continuum. This allows assessments to be made from early nonclinical studies onward as to whether or not metabolite safety is underwritten by exposure in toxicology species. This strategy does not require absolute quantitation of the metabolites in early clinical trials but relies upon comparison of relative exposures between animals and humans using the capabilities of modern analytical techniques. Through this strategy, human disproportionate metabolites can be identified to allow a decision regarding the need for absolute quantitation and direct safety testing of the metabolite. Definitive radiolabeled studies would be initiated following proof of pharmacology or efficacy in humans, and nonclinical safety coverage would be adequately assessed prior to large-scale clinical trials. In cases where metabolite safety is not supported through the parent compound toxicology program, approaches for the direct safety testing of metabolites with regard to general and reproductive toxicology, safety pharmacology, and genetic safety have been defined.
Collapse
Affiliation(s)
- Don Walker
- Pfizer Global Research and Development, Sandwich, Kent CT13 9NJ, United Kingdom.
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Abstract
HPLC detector technology has advanced dramatically over the past 20 years, with a range of highly sensitive and specific detectors becoming available. What is still missing from the bioanalyst’s armoury, however, is a highly sensitive detector that gives an equimolar response independent of the compound. This would allow for quantification of compounds without the requirement for a synthetic standard or a radiolabeled analogue. In particular, such a detector applied to metabolism studies would establish the relative significance of the various metabolic routes. The recently issued US FDA guidelines on metabolites in safety testing (MIST) focus on the relative quantitation of human metabolites being obtained as soon as feasible in the drug-development process. In this article, current detector technology is reviewed with respect to its potential for quantitation without authentic standards or a radiolabel and put in the context of the MIST guidelines. The potential for future developments are explored.
Collapse
|
36
|
Nedderman ANR. Metabolites in safety testing: metabolite identification strategies in discovery and development. Biopharm Drug Dispos 2009; 30:153-62. [DOI: 10.1002/bdd.660] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|